APOA4

(redirected from apoA-IV)

APOA4

A gene on chromosome 11q23 that encodes apolipoprotein A-IV, which is a major component of high-density lipoprotein (HDL) and chylomicrons. It plays a role in chylomicrons and VLDL secretion and catabolism, and is required for efficient activation of lipoprotein lipase by ApoC-II. It is a potent activator of lecithin-cholesterol acyltransferase (LCAT).
Mentioned in ?
References in periodicals archive ?
El principal componente estructural proteico de las HDL es la apoproteina A-I (ApoA-I), y en menor medida, ApoA-II, ApoA-IV, ApoC, ApoE, ApoJ y ApoM (Figura 1); adicionalmente posee enzimas como la lecitina colesterol acil-transferasa (LCAT), paraoxonasa-1 (PON-1), el factor activador de plaquetas acetilhidrolasa, y las proteinas de transferencia de esteres de colesterol (CETP) y de fosfolipidos (PLTP) (10).
Lipoproteinas que interactuan con las HDL (1) Lipoproteina Principales Funcion apoproteinas Quilomicrones ApoB-48, ApoA-I, Transporte de los ApoA-II y ApoA-IV triacilgliceroles y del colesterol obtenidos de la dieta, desde el intestino.
Changes in the apoA-IV composition of HDL are dependent on the disease state, with increases in apoA-IV observed in renal diseases (CKD and endstage renal disease), and decreases in apoA-IV with ACS (139, 140, 170).
151 J] Chronic kidney disease * ApoA-l levels are decreased, while apoA-II and SAA increased in patients with CKD [Kronenberg (170)] * ApoA-IV levels are elevated in patients with CKD [Kronenberg (170)].
It has been found that ApoA-IV has the ability to reduce blood sugar levels and enhance insulin secretion.
Previous studies have found ApoA-IV to be elevated in humans following gastric bypass-coinciding with improvement in symptoms for diabetes.
Carrying out their study on lab mice, Tso's team found that mice deficient in apoA-IV had impaired glucose tolerance and insulin was not secreted to move glucose from the blood stream.
Estos resultados indican la participacion del gen de la ApoA-IV en la no-disyuncion cromosomica.
En el plasma, la mayor parte de la apoA-IV es encontrada como proteina libre y solamente una pequena porcion se une a los quilomicrones y a las lipoproteinas de alta densidad (HDL) (Weinberg & Spector, 1985).
The research published in the current online early edition of the Proceedings of the National Academy of Sciences (PNAS), suggests apoA-IV is a promising new target for developing treatments for Type 2 diabetes.
Studies have also shown that apoA-IV is significantly increased in humans following gastric bypass, and this was coincident with the amelioration of diabetes.
The percentage of ApoA-IV amounts to only one-tenth of that of the ApoA-II (13) and can be neglected.